Antisense Therapy for Infectious Diseases

Overview

Journal Cells

Publisher MDPI

Specialties Biochemistry
Biophysics
Cell Biology
Molecular Biology

Date 2023 Aug 26

PMID 37626929

Authors

Lwanda Abonga Buthelezi

Shandre Pillay

Noxolo Nokukhanya Ntuli

Lorna Gcanga

Reto Guler

Affiliations

Soon will be listed here.

Abstract

Infectious diseases, particularly Tuberculosis (TB) caused by , pose a significant global health challenge, with 1.6 million reported deaths in 2021, making it the most fatal disease caused by a single infectious agent. The rise of drug-resistant infectious diseases adds to the urgency of finding effective and safe intervention therapies. Antisense therapy uses antisense oligonucleotides (ASOs) that are short, chemically modified, single-stranded deoxyribonucleotide molecules complementary to their mRNA target. Due to their designed target specificity and inhibition of a disease-causing gene at the mRNA level, antisense therapy has gained interest as a potential therapeutic approach. This type of therapy is currently utilized in numerous diseases, such as cancer and genetic disorders. Currently, there are limited but steadily increasing studies available that report on the use of ASOs as treatment for infectious diseases. This review explores the sustainability of FDA-approved and preclinically tested ASOs as a treatment for infectious diseases and the adaptability of ASOs for chemical modifications resulting in reduced side effects with improved drug delivery; thus, highlighting the potential therapeutic uses of ASOs for treating infectious diseases.

Citing Articles

Opportunities for Riboswitch Inhibition by Targeting Co-Transcriptional RNA Folding Events.

Stephen C, Palmer D, Mishanina T Int J Mol Sci. 2024; 25(19).

PMID: 39408823 PMC: 11476745. DOI: 10.3390/ijms251910495.

Enabling safer, more potent oligonucleotide therapeutics with bottlebrush polymer conjugates.

Chen P, Wei Y, Sun T, Lin J, Zhang K J Control Release. 2023; 366:44-51.

PMID: 38145661 PMC: 10922259. DOI: 10.1016/j.jconrel.2023.12.035.

BIR: Biomedical Information Retrieval System for Cancer Treatment in Electronic Health Record Using Transformers.

Ahmad P, Liu Y, Khan K, Jiang T, Burhan U Sensors (Basel). 2023; 23(23).

PMID: 38067736 PMC: 10708614. DOI: 10.3390/s23239355.

References

Geary R, Henry S, Grillone L . Fomivirsen: clinical pharmacology and potential drug interactions. Clin Pharmacokinet. 2002; 41(4):255-60. DOI: 10.2165/00003088-200241040-00002. View

New R, Chance M, Thomas S, Peters W . Antileishmanial activity of antimonials entrapped in liposomes. Nature. 1978; 272(5648):55-6. DOI: 10.1038/272055a0. View

Holden K, Stein D, Pierson T, Ahmed A, Clyde K, Iversen P . Inhibition of dengue virus translation and RNA synthesis by a morpholino oligomer targeted to the top of the terminal 3' stem-loop structure. Virology. 2005; 344(2):439-52. DOI: 10.1016/j.virol.2005.08.034. View

Roberts T, Langer R, Wood M . Advances in oligonucleotide drug delivery. Nat Rev Drug Discov. 2020; 19(10):673-694. PMC: 7419031. DOI: 10.1038/s41573-020-0075-7. View

Schottstedt V, Blumel J, Burger R, Drosten C, Groner A, Gurtler L . Human Cytomegalovirus (HCMV) - Revised. Transfus Med Hemother. 2011; 37(6):365-375. PMC: 3048947. DOI: 10.1159/000322141. View

Daraee H, Etemadi A, Kouhi M, Alimirzalu S, Akbarzadeh A . Application of liposomes in medicine and drug delivery. Artif Cells Nanomed Biotechnol. 2014; 44(1):381-91. DOI: 10.3109/21691401.2014.953633. View

Vickers T, Crooke S . The rates of the major steps in the molecular mechanism of RNase H1-dependent antisense oligonucleotide induced degradation of RNA. Nucleic Acids Res. 2015; 43(18):8955-63. PMC: 4605327. DOI: 10.1093/nar/gkv920. View

Hammond S, Aartsma-Rus A, Alves S, Borgos S, Buijsen R, Collin R . Delivery of oligonucleotide-based therapeutics: challenges and opportunities. EMBO Mol Med. 2021; 13(4):e13243. PMC: 8033518. DOI: 10.15252/emmm.202013243. View

. A randomized controlled clinical trial of intravitreous fomivirsen for treatment of newly diagnosed peripheral cytomegalovirus retinitis in patients with AIDS. Am J Ophthalmol. 2002; 133(4):467-74. DOI: 10.1016/s0002-9394(02)01327-2. View

10.

Kim Y . Drug Discovery Perspectives of Antisense Oligonucleotides. Biomol Ther (Seoul). 2023; 31(3):241-252. PMC: 10129852. DOI: 10.4062/biomolther.2023.001. View

11.

Crooke S, Vickers T, Liang X . Phosphorothioate modified oligonucleotide-protein interactions. Nucleic Acids Res. 2020; 48(10):5235-5253. PMC: 7261153. DOI: 10.1093/nar/gkaa299. View

12.

Swenson D, Warfield K, Warren T, Lovejoy C, Hassinger J, Ruthel G . Chemical modifications of antisense morpholino oligomers enhance their efficacy against Ebola virus infection. Antimicrob Agents Chemother. 2009; 53(5):2089-99. PMC: 2681561. DOI: 10.1128/AAC.00936-08. View

13.

Ge Q, Pastey M, Kobasa D, Puthavathana P, Lupfer C, Bestwick R . Inhibition of multiple subtypes of influenza A virus in cell cultures with morpholino oligomers. Antimicrob Agents Chemother. 2006; 50(11):3724-33. PMC: 1635187. DOI: 10.1128/AAC.00644-06. View

14.

Hashimoto M, Nara T, Hirawake H, Morales J, Enomoto M, Mikoshiba K . Antisense oligonucleotides targeting parasite inositol 1,4,5-trisphosphate receptor inhibits mammalian host cell invasion by Trypanosoma cruzi. Sci Rep. 2014; 4:4231. PMC: 3937783. DOI: 10.1038/srep04231. View

15.

Hagedorn P, Persson R, Funder E, Albaek N, Diemer S, Hansen D . Locked nucleic acid: modality, diversity, and drug discovery. Drug Discov Today. 2017; 23(1):101-114. DOI: 10.1016/j.drudis.2017.09.018. View

16.

Roehr B . Fomivirsen approved for CMV retinitis. J Int Assoc Physicians AIDS Care. 2001; 4(10):14-6. View

17.

Qiao Y, Wotring J, Zhang C, Jiang X, Xiao L, Watt A . Antisense oligonucleotides to therapeutically target SARS-CoV-2 infection. PLoS One. 2023; 18(2):e0281281. PMC: 9897518. DOI: 10.1371/journal.pone.0281281. View

18.

Holden K, Harris E . Enhancement of dengue virus translation: role of the 3' untranslated region and the terminal 3' stem-loop domain. Virology. 2004; 329(1):119-33. DOI: 10.1016/j.virol.2004.08.004. View

19.

Springer A, Dowdy S . GalNAc-siRNA Conjugates: Leading the Way for Delivery of RNAi Therapeutics. Nucleic Acid Ther. 2018; 28(3):109-118. PMC: 5994659. DOI: 10.1089/nat.2018.0736. View

20.

Alajlouni R, Seleem M . Targeting listeria monocytogenes rpoA and rpoD genes using peptide nucleic acids. Nucleic Acid Ther. 2013; 23(5):363-7. PMC: 3760085. DOI: 10.1089/nat.2013.0426. View